The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures
Open accessAbstract
Purpose: To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. Patients and Methods: Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays. Results: RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation–associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223. Conclusion: RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationCytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Stem cell gene expression programs influence clinical outcome in human leukemia
Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2415 · Cited by 1,041
Self-citationFazi, F., Rosa, A., Fatica, A., Gelmetti, V., De Marchis, M. L., Nervi, C., & Bozzoni, I. (2005) · Cell · doi:10.1016/j.cell.2005.09.023 · Cited by 894
Döhner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rücker, F. G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., & for the AML Study Group (AMLSG) (2005) · Blood · doi:10.1182/blood-2005-05-2164 · Cited by 849
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Marcucci, G., Maharry, K., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763
Self-citationCytogenetics in acute leukemia
Mrózek, K., Heerema, N. A., & Bloomfield, C. D. (2004) · Blood Reviews · doi:10.1016/s0268-960x(03)00040-7 · Cited by 659
Self-citationWhitman, S. P., Archer, K. J., Lin, F., Baldus, C. D., Becknell, B., Carlson, B. D., Carroll, A. J., Mrózek, K., Vardiman, J., George, S. L., et al. (2001) · PubMed · Cited by 633
Self-citationlet-7 microRNAs in development, stem cells and cancer
Büssing, I., Slack, F. J., & Großhans, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.07.001 · Cited by 607
Mrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2007) · Blood · doi:10.1182/blood-2006-06-001149 · Cited by 552
Self-citationFröhling, S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.060 · Cited by 458
Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A. S., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 456
Osato, M., Asou, N., Abdalla, E., Hoshino, K., Yamasaki, H., Okubo, T., Suzushima, H., Takatsuki, K., Kanno, T., Shigesada, K., et al. (1999) · Blood · doi:10.1182/blood.v93.6.1817.406k36_1817_1824 · Cited by 397
Gentles, A. J. (2010) · JAMA · doi:10.1001/jama.2010.1862 · Cited by 395
Tang, J.-L., Hou, H.-A., Chen, C.-Y., Liu, C.-Y., Chou, W.-C., Tseng, M.-H., Huang, C.-F., Lee, F.-Y., Liu, M.-C., Yao, M., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223784 · Cited by 344
Becker, H., Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., Paschka, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1496 · Cited by 338
Self-citationMarcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Vukosavljevic, T., Paschka, P., Whitman, S. P., Langer, C., Baldus, C. D., Liu, C.-G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5554 · Cited by 302
Self-citationHarada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281
Metzeler, K. H., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Becker, H., Curfman, J., Holland, K. B., Schwind, S., Whitman, S. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7742 · Cited by 280
Self-citationMetzeler, K. H., Becker, H., Maharry, K., Radmacher, M. D., Kohlschmidt, J., Mrózek, K., Nicolet, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-368225 · Cited by 275
Self-citationPoint mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
Osato, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207779 · Cited by 268
Whitman, S. P., Ruppert, A. S., Radmacher, M. D., Mrózek, K., Paschka, P., Langer, C., Baldus, C. D., Wen, J., Racke, F., Powell, B. L., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107946 · Cited by 266
Self-citationSchnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C., & Haferlach, T. (2011) · Blood · doi:10.1182/blood-2009-11-255976 · Cited by 265
Preudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J. L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000) · Blood · doi:10.1182/blood.v96.8.2862 · Cited by 263
Paschka, P., Marcucci, G., Ruppert, A. S., Whitman, S. P., Mrózek, K., Maharry, K., Langer, C., Baldus, C. D., Zhao, W., Powell, B. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2058 · Cited by 258
Self-citationMarcucci, G., Metzeler, K. H., Schwind, S., Becker, H., Maharry, K., Mrózek, K., Radmacher, M. D., Kohlschmidt, J., Nicolet, D., Whitman, S. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2092 · Cited by 251
Self-citationBaldus, C. D., Tanner, S. M., Ruppert, A. S., Whitman, S. P., Archer, K. J., Marcucci, G., Caligiuri, M. A., Carroll, A. J., Vardiman, J. W., Powell, B. L., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0359 · Cited by 241
Self-citationDistinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia
Dixon-McIver, A., East, P., Mein, C. A., Cazier, J.-B., Molloy, G., Chaplin, T., Andrew Lister, T., Young, B. D., & Debernardi, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002141 · Cited by 225
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.
Caligiuri, M. A., Strout, M. P., Lawrence, D. D., Arthur, D., Baer, M., Yu, F., Knuutila, S., Mrózek, K., Oberkircher, A. R., Marcucci, G., et al. (1998) · PubMed · Cited by 224
Self-citationVirappane, P., Gale, R., Hills, R., Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0333 · Cited by 218
Langer, C., Radmacher, M. D., Ruppert, A. S., Whitman, S. P., Paschka, P., Mrózek, K., Baldus, C. D., Vukosavljevic, T., Liu, C.-G., Ross, M. E., et al. (2008) · Blood · doi:10.1182/blood-2007-11-124958 · Cited by 192
Self-citationCaligiuri, M. A., Strout, M. P., Schichman, S. A., Mrózek, K., Arthur, D., Herzig, G. P., Baer, M., Schiffer, C. A., Heinonen, K., Knuutila, S., et al. (1996) · PubMed · Cited by 185
Self-citationLanger, C., Marcucci, G., Holland, K. B., Radmacher, M. D., Maharry, K. S., Paschka, P., Whitman, S. P., Mrózek, K., Baldus, C. D., Vij, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6110 · Cited by 178
Self-citationChen, C., Lin, L., Tang, J., Ko, B.-S., Tsay, W., Chou, W., Yao, M., Wu, S., Tseng, M., & Tien, H. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06811.x · Cited by 152
Georgantas, R. W., Tanavde, V., Malehorn, M., Heimfeld, S., Chen, C., Carr, L., Martínez-Murillo, F., Riggins, G., Kowalski, J., & Civin, C. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3247 · Cited by 140
Dicker, F., Haferlach, C., Kern, W., Haferlach, T., & Schnittger, S. (2007) · Blood · doi:10.1182/blood-2007-02-072595 · Cited by 127
Prognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal Cytogenetics
Gaidzik, V. I., & Döhner, K. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.005 · Cited by 110
Whitman, S. P., Ruppert, A. S., Marcucci, G., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069831 · Cited by 107
Self-citationToren, A., Bielorai, B., Jacob‐Hirsch, J., Fisher, T., Kreiser, D., Moran, O., Zeligson, S., Givol, D., Yitzhaky, A., Itskovitz‐Eldor, J., et al. (2005) · Stem Cells · doi:10.1634/stemcells.2004-0317 · Cited by 94
Identification of RUNX1/AML1 as a classical tumor suppressor gene
Silva, F. P. G., Morolli, B., Storlazzi, C. T., Anelli, L., Wessels, H. M. C., Bezrookove, V., Kluin‐Nelemans, H. C., & Giphart-Gassler, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206141 · Cited by 74
Murray, L. J., Bruno, E., Uchida, N., Hoffman, R., Nayar, R., Yeo, E. L., Schuh, A. C., & Sutherland, D. R. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00071-5 · Cited by 70
Mrózek, K. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000002 · Cited by 70
Self-citationHe, X., Gonzalez-Pena, V., Tsang, A. H., Thompson, J., Tsang, T. C., & Harris, D. T. (2005) · Stem Cells and Development · doi:10.1089/scd.2005.14.188 · Cited by 68
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7
Langabeer, S. E., Gale, R. E., Rollinson, S. J., Morgan, G. J., & Linch, D. C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10031 · Cited by 62
Matsuno, N., Osato, M., Yamashita, N., Yanagida, M., Nanri, T., Fukushima, T., Motoji, T., KUSUMOTO, S., Towatari, M., Suzuki, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403160 · Cited by 60
Silva, F. P. G., Swagemakers, S. M. A., Erpelinck-Verschueren, C. A. J., Wouters, B. J., Delwel, R., Vrieling, H., van der Spek, P. J., Valk, P. J. M., & Giphart-Gassler, M. (2009) · Blood · doi:10.1182/blood-2009-03-211334 · Cited by 55
Molecular resolution of the B cell landscape
Santos, P. M. L., & Borghesi, L. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.11.014 · Cited by 22
Cited by
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Self-citationDöhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationDöhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Self-citationAcute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 541
Metadata
- Authors
- Mendler, J. H., Maharry, K., Radmacher, M. D., Mrózek, K., Becker, H., Metzeler, K. H., Schwind, S., Whitman, S. P., Khalife, J., Kohlschmidt, J., Nicolet, D., Powell, B. L., Carter, T. H., Wetzler, M., Moore, J. O., Kolitz, J. E., Baer, M. R., Carroll, A. J., Larson, R. A., Caligiuri, M. A., Marcucci, G., & Bloomfield, C. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-09-01
- Volume
- 30
- Issue
- 25
- Pages
- 3109-3118
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153953632
- Cited by
- 268
- References
- 54
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.